Meloxicam SBEβCD Composition for Faster Oral Absorption

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and slow onset of pain relief.

Innovation Solution

Formulating meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and bicarbonate to create an inclusion complex, enhancing solubility and bioavailability, and combining it with rizatriptan for rapid and sustained pain relief.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If meloxicam is used as a conventional NSAID, then it provides anti-inflammatory and analgesic activities, but it has poor aqueous solubility which reduces bioavailability and slows onset of pain relief

Engineering Contradiction:
ImprovebioavailabilityVSAvoidonset of pain relief
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent uses cyclodextrins as intermediary carriers to solubilize meloxicam. The cyclodextrin molecules form inclusion complexes with meloxicam, where the hydrophobic interior of the cyclodextrin ring accommodates the meloxicam molecule while the hydrophilic exterior interacts with aqueous environments, thereby enhancing solubility and bioavailability without altering the core meloxicam structure

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the physical-chemical parameters of meloxicam by forming inclusion complexes with cyclodextrins. This changes the solubility parameter of meloxicam from poor to improved, and accelerates the dissolution rate, leading to faster onset of action while maintaining the same pharmacological activity

Inventive Principle:
Principle #35Parameter changes

2Reliability

If meloxicam is formulated with cyclodextrins to increase solubility, then bioavailability improves, but the formulation complexity increases

Engineering Contradiction:
ImprovebioavailabilityVSAvoidformulation complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The cyclodextrin-meloxicam inclusion complex forms through self-assembly in aqueous solution without requiring complex formulation processes. The hydrophobic interaction between cyclodextrin and meloxicam drives spontaneous complex formation, eliminating the need for sophisticated manufacturing equipment or multi-step processing while achieving enhanced solubility

Inventive Principle:
Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination significantly increases meloxicam's solubility and absorption rate, providing rapid and sustained pain relief, reducing the need for rescue medication and improving treatment outcomes in conditions like migraine and arthritis.

Implementation Method 1

cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring

Methodology Applied
Scientific EffectInclusion complex formation: Solvation

Implementation Method 2

cyclodextrin compounds are also known to aggregate around a drug in a micelle-type structure

Methodology Applied
Scientific EffectMicelle formation: Emulsion

Data Source

PatentUS12472255B2Pharmaceutical compositions comprising meloxicam
Publication Date: 2025.11.18 AXSOME THERAPEUTICS INC
  • US12472255B2 patent drawing
  • US12472255B2 patent drawing
  • US12472255B2 patent drawing

AI summary

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.